| Question 1: How is CT used to attenuation correct SPECT data? |
| Reference: | Investigation of the relationship between linear attenuation coefficients and CT Hounsfield units using radionuclides for SPECT. Brown S, Bailey DL, Willowson K, Baldock C. Appl Radiat. Isot. 2008; 66: 1206-1212 |
| Choice A: | The Hounsfield Unit factors from CT can be directly used to attenuation correct the SPECT data |
| Choice B: | A bi-linear conversion of attenuation at CT energies to SPECT is used irrespective of the imaged radionuclide |
| Choice C: | A bi-linear conversion of attenuation at CT energies to SPECT is used which is specific to the imaged radionuclide |
| Choice D: | CT cannot be used to attenuation correct SPECT data. |
| Question 2: When quantifying SPECT uptake in a small feature, which physical effect degrades the measured uptake the most? |
| Reference: | Quantitative Accuracy of Dopaminergic Neurotransmission Imaging with 123I SPECT. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. J Nucl Med 2003; 44(7):1184-1193 |
| Choice A: | Scatter |
| Choice B: | Attenuation |
| Choice C: | Deadtime |
| Choice D: | Spatial resolution |
| Question 3: In dosimetry for radionuclide therapy, what role does quantitative SPECT play? |
| Reference: | MIRD pamphlet 23: Quantitative SPECT for patient-specific 3-dimensaional dosimetry in internal radionuclide therapy. Dewaraja Y, Frey E, Sgouros G, Brill A, Roberson P, Zanzonico P, Ljungberg. J Nucl Med 2012; 53(8): 1310-1325 |
| Choice A: | Using multiple timepoint data, it directly derives dose on a voxel level |
| Choice B: | Using multiple timepoint data, it can directly derive accumulated activity in organs and tumors |
| Choice C: | It is used to derive S-values |
| Choice D: | It is used in geometric mean calculations |
| Question 4: Identify which of the following statement is FALSE regarding the role of 99mTc sulfur colloid or 99mTc-mebrofenin liver SPECT/CT scans: |
| Reference: | Bennink et al., Monitoring of total and regional liver function after SIRT, Frontiers in Onc 4: 152, 2014. |
| Choice A: | It is used for qualitative and spatial assessment of liver function |
| Choice B: | It is used in radiation treatment planning of liver to avoid functional liver hepatocytes |
| Choice C: | It gets concentrated in liver tumors for better identification of disease |
| Choice D: | It is an FDA-approved agent |
| Question 5: Identify which of the following statement is FALSE regarding the role of 99mTc macro-aggregated albumin (MAA) in lung SPECT/CT scans |
| Reference: | Meng et al., Changes in Functional Lung Regions During the Course of Radiation Therapy and Their Potential Impact on Lung Dosimetry for Non-Small Cell Lung Cancer, IJROBP 89(1): 145-151, 2014. |
| Choice A: | It is used for qualitative and spatial assessment of lung perfusion |
| Choice B: | It is used in radiation treatment planning of lung to avoid well perfused lung volumes |
| Choice C: | It gets concentrated in lung tumors for better identification of disease |
| Choice D: | It is an FDA-approved agent |
| Question 6: What are the benefits of post-therapy verification imaging with 90Y SPECT/CT? |
| Reference: | Wondergem M et al., 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization, J Nucl Med 54(8): 1294-1301, 2013. |
| Choice A: | The 99mTc-MAA distribution may be different than the final in vivo 90Y distribution |
| Choice B: | The radiation doses delivered are proportional to the 90Y SPECT/CT image intensity |
| Choice C: | Only (A) is True |
| Choice D: | Both (A) and (B) are True |
